Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis
Frontiers in Pharmacology · 19.07.2023 · 14
DOI: 10.3389/fphar.2023.1216059 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.07.2023. Verfasst von Xinyi He und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (HCC) is a serious complication of cirrhosis. Currently, non-selective beta-blockers (NSBBs) are commonly used to treat portal hypertension in patients with cirrhosis. The latest research shows that NSBBs can induce apoptosis and S-phase arrest in liver cancer cells and inhibit the development of hepatic vascular endothelial cells, which may be effective in preventing HCC in cirrhosis patients.
Aim
To determine the relationship between different NSBBs and HCC incidence in patients with cirrhosis.
Methods
We searched the Cochrane database, MEDLINE, EMBASE, PubMed, and Web of Science. Cohort studies, case‒control studies, and randomized controlled trials were included if they involved cirrhosis patients who were divided into an experimental group using NSBBs and a control group with any intervention. Based on heterogeneity, we calculated odds ratio (OR) and 95% confidence interval (CI) using random-effect models. We also conducted subgroup analysis to explore the source of heterogeneity. Sensitivity analysis and publication bias detection were performed.
Results
A total of 47 studies included 38 reporting HCC incidence, 26 reporting HCC-related mortality, and 39 reporting overall mortality. The HCC incidence between the experimental group and the control group was OR = 0.87 (0.69 and 1.10), p = 0.000, and I 2 = 81.8%. There was no significant association between propranolol (OR = 0.94 and 95%CI 0.62–1.44) or timolol (OR = 1.32 and 95%CI 0.44–3.95) and HCC incidence, while the risk of HCC decreased by 26% and 38% with nadolol (OR = 0.74 and 95%CI 0.64–0.86) and carvedilol (OR = 0.62 and 95%CI 0.52–0.74), respectively.
Conclusion
Different types of NSBB have different effects on the incidence of patients with cirrhosis of the liver, where nadolol and carvedilol can reduce the risk. Also, the effect of NSBBs may vary in ethnicity. Propranolol can reduce HCC incidence in Europe and America. Systematic Review Registration: identifier https://CRD42023434175 , https://www.crd.york.ac.uk/PROSPERO/ .
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
- Clinical Department I, China Medical University, Shenyang, Liaoning, China.
- First Clinical Medical College, China Medical University, Shenyang, Liaoning, China.
- Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
He, X., Zhao, Z., Jiang, X., & Sun, Y. (2023). Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1216059
Vancouver
He X, Zhao Z, Jiang X, Sun Y. Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1216059
BibTeX
@article{He2023,
author = {He, Xinyi and Zhao, Zimo and Jiang, Xi and Sun, Yan},
title = {Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1216059}
}
EUVIMED